Adrenergic modifiers - Biotech, Pharma and Life Science Channel

23:08 EST 4th March 2015 | BioPortfolio

PubMed Articles [368 Associated PubMed Articles listed on BioPortfolio]

Polymorphisms in Oxytocin and α1a Adrenergic Receptor Genes and Their Effects on Production Traits in Dairy Buffaloes.

The use of molecular markers may auxiliary the buffalo breeding. The oxytocin (OXT) and the adrenergic receptor α1A (ADRA1A) may be involved in milk ejection in ruminants. The aim of this study was t...

Direct detection of free fatty acids in edible oils using supercritical fluid chromatography coupled with mass spectrometry.

Determination of free fatty acids (FFAs) in food products is of enormous interest mainly because they are related to the quality and authenticity of the oils. In this study, supercritical fluid chroma...

Pathway-driven discovery of epilepsy genes.

Epilepsy genes deliver critical insights into the molecular control of brain synchronization and are revolutionizing our understanding and treatment of the disease. The epilepsy-associated genome is r...

Raman Response of Network Modifier Cations in Alumino-Silicate Glasses.

Raman scattering is performed in three sets of aluminosilicate glasses with light cations and concentrations varying from peralcaline to peraluminate domain. The depolarized spectra highlight two cati...

The immunology of influenza virus-associated bacterial pneumonia.

Infection with influenza virus has been a significant cause of morbidity and mortality for more than a hundred years. Severe disease and increased mortality often results from bacterial super-infectio...

β-adrenergic effects on cardiac myofilaments and contraction in an integrated rabbit ventricular myocyte model.

A five-state model of myofilament contraction was integrated into a well-established rabbit ventricular myocyte model of ion channels, Ca(2+) transporters and kinase signaling to analyze the relative ...

Vitamin D₃ Supplementation in Batswana Children and Adults with HIV: A Pilot Double Blind Randomized Controlled Trial.

Since vitamin D insufficiency is common worldwide in people with HIV, we explored safety and efficacy of high dose cholecalciferol (D₃) in Botswana, and evaluated potential modifiers of serum 25 hyd...

Dosage of the Abcg1-U2af1 Region Modifies Locomotor and Cognitive Deficits Observed in the Tc1 Mouse Model of Down Syndrome.

Down syndrome (DS) results from one extra copy of human chromosome 21 and leads to several alterations including intellectual disabilities and locomotor defects. The transchromosomic Tc1 mouse model c...

Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists.

Do sedatives engage natural sleep pathways? It is usually assumed that anesthetic-induced sedation and loss of righting reflex (LORR) arise by influencing the same circuitry to lesser or greater exten...

Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling.

Hypersecretion of norepinephrine (NE) and angiotensin II (AngII) is a hallmark of major prevalent cardiovascular diseases that contribute to cardiac pathophysiology and morbidity. Herein, we explore w...

News Articles [44 Associated News Articles listed on BioPortfolio]

Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society

The Rheumatology Nurses Society (RNS) is dedicated to the public’s expectation of excellence in care and safe practice for patients with rheumatic diseases. Greenville, SC (PRWEB) March 03, 2015 Th...

Neuronal ensembles sufficient for recovery sleep and the sedative actions of α2 adrenergic agonists

The authors use TetTag pharmacogenetics to mark neuronal ensembles activated in the preoptic hypothalamus during dexmedeotomidine-induced sedation or recovery sleep. When these ensembles were selectiv...

Sosei to acquire Heptares for up to $400M

Sosei Group Corp. (Tokyo:4565) will acquire Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) for $180 million up front and up to $220 million in milestones.Sosei will receive Heptares' StaR drug ...

IMCD to Expand Plastic Additives Partnership with Dow into GSA and the UK

IMCD is expanding its partnership with Dow Europe GmbH for Paraloid impact modifiers and Surecel processing aids into the GSA region (Germany, Switzerland and Austria) and the UK.

GSK expects Advair price crunch, ViiV IPO decision

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects continued price pressure on respiratory drug Advair salmeterol/fluticasone propionate this year and said it is likely to reveal a decision on a partial ...

Rett Syndrome Research Trust Awards $5.8 Million to Advance the Development of Treatments and Cures for Rett Syndrome and MECP2 Disorders

Today the Rett Syndrome Research Trust (RSRT) announced research investments of $5.8 million awarded in 2014. RSRT’s sole and urgent goal is to abolish Rett Syndrome and related disorders. Trumbull,...

Theravance Biopharma, Mylan strike COPD deal

Theravance Biopharma Inc. (NASDAQ:TBPH) and Mylan Inc. (NASDAQ:MYL) entered a development and commercialization agreement for nebulized TD-4208 to treat chronic obstructive pulmonary disease (COPD) an...

Box: Global Blood Therapeutics Inc. Corporate Profile

Battling blood Global Blood Therapeutics Inc. South San Francisco, Calif. Technology: Hemoglobin modifiers for blood disorders Disease focus: Hematology, inflammation Clinical status: Phase I/II Found...

New book on retinal disorders from Cold Spring Harbor Laboratory Press

(Cold Spring Harbor Laboratory) 'Retinal Disorders' from Cold Spring Harbor Laboratory Press reviews recent work on retinal diseases, describing their genetic and molecular basis, their clinical chara...

Vicus Therapeutics Announces Safety and Survival Benefit of VT-122 in Combination with Anti-Cancer Therapies for Advanced Liver and Pancreatic Cancers

MORRISTOWN, N.J., Jan. 16, 2015 /PRNewswire/ -- Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, today announc...

Events [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of i...

Innate Therapeutics Limited

Innate Therapeutics Limited is a public unlisted biopharmaceutical company based in Auckland. The company is focused on the development of a new generation of immune response modi...

Clinical Trials [84 Associated Clinical Trials listed on BioPortfolio]

Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects

This is a Phase 3, multicenter, randomised, double-blind, placebo-controlled trial of darbepoetin alfa 500 μg administered once every 3 weeks (Q3W) to approximately 141 low or intermediat...

TAKO-TSUBO Cardiomyopathy and Genetic

This is a case-control association study with multicentric prospective recruitment. Tako-TSUBO cardiomyopathy is a new clinical entity mimicking an acute coronary syndrome. It is characte...

Molecular Immunohematology in Ethiopian Sub-Populations

Alloimmunization to blood products in transfused patients is a recognized management challenge in the clinical setting. In particular the ethnic and racial specificity of RBC antigens and ...

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia ar...

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use o...

Stress During Deep Sedation With Propofol With and Without Alfentanil

This is a randomized clinical trial of deep procedural sedation with propofol with and without supplemental alfentanil. Patients will be assessed for total and fractionated serum catechol...

Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage

The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic ...

Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM)

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic recept...

Occluded Artery Trial (OAT)

The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composi...

Medical and Biotech [MESH] Definitions

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.

A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). beta-3 Adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS.

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Adrenergic modifiers market research data and corporate reports here

Channels Quicklinks